GUIDEWIRE
23.3.2022 07:02:05 CET | Business Wire | Press release
Guidewire (NYSE: GWRE) today announced that it has opened its new EMEA headquarters 10 years after the company opened its first office in Dublin. Based in Blanchardstown, the new office building occupies 85,000ft² and is evidence of Guidewire’s continued commitment to Ireland and its customers across Europe. Adapting to the new world of work, Guidewire is offering employees fully remote and hyperflexible working practices. As well as providing employees with a state-of-the-art work environment, the office also includes an executive briefing centre for its customer and partner community across the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006033/en/
Since 2011, Guidewire’s Dublin base has grown to become the company’s largest employee community in Europe and outside of the USA, including a diverse range of 35+ nationalities. Guidewire anticipates scaling headcount by about 150 new recruits to around 600 staff over the next two to three years and is actively hiring across a range of positions, from entry-level graduate roles to business analysts, cloud operations, consulting managers, engineering, HR & Recruitment, project managers, specialist cloud transition roles, and technology consultants.
Since 2016 Guidewire Dublin has made the top 20 in the Great Place to Work, including 10th place in Ireland’s Best Workplaces 2021 for best large company.
“This is an exciting moment for Guidewire in Ireland as we open our new EMEA HQ, reflecting the enormous contribution of our team to the Guidewire corporate and customer community,” said Niall Lalor, Ireland country manager, Guidewire. “As the company has grown and evolved over the past 10 years in Ireland, I’m hugely proud that we have retained our strong sense of identity and close-knit culture throughout. We’ve still only scratched the surface and look forward to growing our talented team even more across the country, with Guidewire in Dublin well placed as a hub for innovation that supports our business both in EMEA and globally.”
The Irish operations include Customer & Cloud Operations, Delivery Services, and Product Development, with teams that have spearheaded Guidewire’s digital products, created specific local solutions for European customers, as well as managed the implementations and support of the company’s first cloud customers. The siting of the cloud team in Dublin also takes advantage of access to top new graduates from Ireland, the wider European Union, and beyond.
“Ireland has been central to Guidewire’s international growth over the past 10 years,” said Mike Rosenbaum, chief executive officer, Guidewire. “It’s nothing new to say that the world has witnessed extraordinary changes over the past two years and the insurance industry is no exception. Guidewire continues to be an indispensable partner to our 450+ customers around the world. Guidewire aspires to design, build, and run a mission critical cloud service, and our team in Ireland is critical to making this a reality.”
Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar, TD, said “I’m so pleased Guidewire has chosen Blanchardstown for its new EMEA headquarters. Guidewire is a leading player in the software industry and this expansion, which will create an additional 150 highly skilled jobs, demonstrates the company’s continued commitment to Ireland after 10 years. I wish the team every success with their expansion plans.”
Commenting on the news Mary Buckley, Executive Director, IDA Ireland, said “Today’s announcement demonstrates Guidewire’s continued confidence in the availability of a highly skilled and talented workforce in Ireland to further support its evolution and to deliver on its strategic corporate goals. I wish the team continued success in their new office building and offer the company the ongoing support of IDA Ireland.”
Further details are available at: https://careers.guidewire.com/location/dublin
Dublin office video:
https://players.brightcove.net/929656735001/41G8Cuaute_default/index.html?videoId=6300984518001
About Guidewire
Guidewire is the platform general insurers trust to engage, innovate, and grow efficiently. We combine digital, core, analytics, and AI to deliver our platform as a cloud service. More than 450 insurers, from new ventures to the largest and most complex in the world, run on Guidewire.
As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localisation, and innovation.
For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .
NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322006033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
